Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - ENDO HEALTH SOLUTIONS INC. | d311239d8k.htm |
 Exhibit 99.1
Cowen and Company
32nd Annual Health Care Conference
March 7, 2012
©2012 Endo, Inc. All rights reserved.
1 |
 ©2012 Endo Pharmaceuticals, Inc.
2
Forward Looking Statements
This presentation contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements including
words such as “believes,” “expects,”
“anticipates,”
“intends,”
“estimates,”
“plan,”
“will,”
“may,”
“look forward,”
“intend,”
“guidance,”
“future”
or similar expressions are forward-looking statements. Because these
statements reflect our current views, expectations and beliefs concerning
future events, these forward-looking statements involve risks and
uncertainties. Investors should note that many factors,
as
more
fully
described
under
the
caption
“Risk
Factors”
in
our
Form
10-K,
Form
10-Q
and Form 8-K filings with the Securities and Exchange Commission and as
otherwise enumerated herein or therein, could affect our future financial
results and could cause our actual results to differ materially from those
expressed in forward-looking statements contained in our Annual Report
on Form 10-K. The forward-looking statements in this presentation are qualified by
these risk factors. These are factors that, individually or in the aggregate, could
cause our actual results to differ materially from expected and historical
results. We assume no obligation to publicly update any forward-looking
statements, whether as a result of new information, future developments or
otherwise. |
 Solutions for 21
st
Century Healthcare
©2012 Endo, Inc. All rights reserved.
3
I.
Our Diversified Business
II.
Growth Drivers
III.
Commitment to Innovation
IV.
2012 Financial Guidance
V.
Summary |
 4
ACCESS
OUTCOMES
ECONOMICS
Healthcare
Value
©2012 Endo Pharmaceuticals, Inc. |
 Solid
Track Record of Sales Growth Endo expects to report more than $3 Billion in
2012 sales 5
Sustaining our Growth
©2012 Endo Pharmaceuticals, Inc. |
 STRONG CASH FLOW GENERATION
6
©2012 Endo Pharmaceuticals, Inc. |
 DIVERSIFIED HEALTHCARE SOLUTIONS COMPANY
7
©2012 Endo Pharmaceuticals, Inc.
93%
7%
Branded Pharmaceuticals
Generics
56%
19%
18%
7%
Branded Pharmaceuticals
Generics
Devices
Services**
Revenue Mix*
Revenue Mix
Endo -
2008
Endo -
2011 |
 Commitment to Innovation
8
Branded
Pharmaceuticals
Medical Devices
Generic
Pharmaceuticals
Generic Development
•
Continually enhancing
existing products
•
Recent advances:
GreenLight™
XPS
Laser Console
MoXy™
Laser Fiber
AdVance™
XP
(OUS)
•
Developing treatments in
new areas
Topas™
sling
Cryotherapy
•
Exploring new emerging
technologies
•
Key Therapeutic Areas
•
Pain
•
Oncology
•
Endocrinology
•
Semi-Virtual R&D Model
•
Global Partnerships
•
Discovery
•
Early Development
•
Development Pipeline
Supplements strong
commercial base growth
©2012 Endo Pharmaceuticals, Inc.
ANDA
Filings
~50 Current
ANDA Reviews
ANDA
Approvals
AVEED™
Long Acting Injectable
Testosterone
BEMA®
Buprenorphine
(Ph. III)
Pain
Urocidin
™
(Ph. III)
Bladder Cancer
Androgen Receptor Antagonist
Castration Resistant Prostate Cancer
(Ph. I)
(NDA) |
 New
Phase III BEMA ®
Buprenorphine
9
•
Complements pain therapeutics portfolio
•
Draws upon existing expertise in the development
and commercialization of opioids
•
Key Financial Terms:
o
$30 million upfront payment to BDSI
o
$150 million in potential milestone payments
o
Contingent on IP, Clinical and Regulatory events
and designated sales levels
o
Tiered royalties on net sales in the U.S.
©2012 Endo Pharmaceuticals, Inc. |
 2012
Guidance 10
Guidance
Revenue range
$3.15B -
$3.30B
Adjusted diluted EPS range
$5.00 -
$5.20
Reported (GAAP) diluted EPS range
$2.60 -
$2.80
©2012 Endo Pharmaceuticals, Inc. |
 2012
Value Creation Opportunities 11
•
Successfully
launch
new
formulation
of
Opana®
ER
•
Support the future growth of Qualitest
o
Invest capital to capture growing demand for products
o
Exceed cost synergies assumed at time of Qualitest acquisition
•
Invest in AMS to accelerate growth
o
AMS/Endo pilot program updates in first half 2012
o
Invest in R&D to accelerate advance of new products to market
•
Maximize operating cash flow to pay down debt
o
Expect ~$500M of cumulative debt repayments to be completed by
end of Q1 2012 on our existing Term Loan indebtedness
©2012 Endo Pharmaceuticals, Inc. |
 ©2012 Endo, Inc. All rights reserved.
12 |
 ©2012 Endo Pharmaceuticals, Inc.
13
Reconciliation of Non-GAAP Measures
For an explanation of Endo’s reasons for using non-GAAP measures, see Endo’s
Current Report on Form 8-K filed today with the Securities and Exchange
Commission Reconciliation of Projected GAAP Diluted Earnings Per Share to Adjusted
Diluted Earnings Per Share Guidance for the Year Ending December 31, 2012
Lower End of Range
Upper End of Range
Projected GAAP diluted income per
common share
$2.60
$2.80
Upfront and milestone-related payments to partners
$0.76
$0.76
Amortization of commercial intangible assets and
inventory step-up
$1.89
$1.89
Acquisition and integration costs related to recent
acquisitions.
$0.10
$0.10
Interest expense adjustment for ASC 470-20 and other
treasury items
$0.21
$0.21
Tax effect of pre-tax adjustments at the applicable tax
rates and certain other expected cash tax savings as a
result of recent acquisitions
($0.56)
($0.56)
Diluted adjusted income per common
share guidance
$5.00
$5.20
The company's guidance is being issued based on certain assumptions including:
•Certain of the above amounts are based on estimates and there
can be no assurance that Endo will achieve these results
•Includes all completed business development transactions as of
March 7, 2012 |
 Cowen and Company
32nd Annual Health Care Conference
March 7, 2012
©2012 Endo, Inc. All rights reserved.
14 |